Zeng Daxiong, Wang Cangguo, Mu Chuanyong, Su Meiqin, Mao Jingyu, Huang Jianan, Xu Jiayue, Shao Lin, Li Bing, Li Haiyan, Li Bingsi, Zhao Jun, Jiang Junhong
Department of Respiratory Medicine, Dusu Lake Hospital to Soochow University, Suzhou, China.
Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ann Transl Med. 2021 Jul;9(13):1080. doi: 10.21037/atm-21-2579.
Differentiating malignant lung tumors from benign pulmonary nodules is a great challenge. While the analysis of bronchoalveolar lavage fluid (BALF) is used for diagnosing infections and interstitial lung diseases, there is limited evidence to support its use for lung cancer diagnosis. This study aimed to interrogate the potential of using BALF cell-free DNA (cfDNA) to discriminate malignant lesions from benign nodules.
Fifty-three patients with solid pulmonary nodules (≤2 cm) were prospectively enrolled, including 21 confirmed with benign disease and 32 with malignant tumors. Mutations were profiled for 30 tumor tissues and 40 BALFs. Paired BALFs and plasma from 48 patients underwent DNA methylation profiling. A methylome-based classification model was developed for BALF and plasma separately.
Among the 30 patients with paired tissues and BALFs, 96.7% and 70% had alterations detected from their tissues (79 alterations) and BALFs (53 alterations), respectively. Using tissues as references, BALFs revealed 14 new alterations and missed 41. BALF mutation displayed a sensitivity of 71%, specificity of 77.8%, and accuracy of 72.5% in detecting lung cancer. BALF methylation achieved an accuracy of 81.3%, with both sensitivity and specificity being 81%. Plasma methylation showed a 66.7% sensitivity, 71.4% specificity, and 68.8% accuracy. BALF methylation also demonstrated 82.4% sensitivity in stage I patients. Parallel bronchoscopy, lavage cytology, and bronchial brushing demonstrated an inferior sensitivity of 23%, 3.1%, and 9.7%, respectively, compared with BALF methylation and mutation (P<0.0001).
BALF cfDNA can serve as a liquid biopsy media for both mutation and methylation profiling, demonstrating better sensitivities in distinguishing small malignant tumors from benign nodules than conventional methods.
Lung cancer diagnosis; pulmonary nodule; bronchoalveolar lavage fluid (BALF); methylation; genomic mutation.
区分恶性肺肿瘤与良性肺结节是一项巨大挑战。虽然支气管肺泡灌洗液(BALF)分析用于诊断感染和间质性肺疾病,但支持其用于肺癌诊断的证据有限。本研究旨在探究使用BALF游离DNA(cfDNA)鉴别恶性病变与良性结节的潜力。
前瞻性纳入53例实性肺结节(≤2 cm)患者,其中21例确诊为良性疾病,32例为恶性肿瘤。对30个肿瘤组织和40份BALF进行突变分析。对48例患者的配对BALF和血浆进行DNA甲基化分析。分别为BALF和血浆建立基于甲基化组的分类模型。
在30例有配对组织和BALF的患者中,分别有96.7%和70%的患者在其组织(79处改变)和BALF(53处改变)中检测到改变。以组织为参照,BALF发现了14处新改变,漏检了41处。BALF突变检测肺癌的敏感性为71%,特异性为77.8%,准确性为72.5%。BALF甲基化的准确性为81.3%,敏感性和特异性均为81%。血浆甲基化的敏感性为66.7%,特异性为71.4%,准确性为68.8%。BALF甲基化在I期患者中的敏感性也为82.4%。与BALF甲基化和突变相比,同期支气管镜检查、灌洗细胞学检查和支气管刷检的敏感性分别为23%、3.1%和9.7%,较低(P<0.0001)。
BALF cfDNA可作为用于突变和甲基化分析的液体活检介质,在区分小的恶性肿瘤与良性结节方面比传统方法具有更高的敏感性。
肺癌诊断;肺结节;支气管肺泡灌洗液(BALF);甲基化;基因组突变